Investors eyeing a purchase of Keryx Biopharmaceuticals Inc. (Symbol: KERX) stock, but cautious about paying the going market price of $7.12/share, might benefit from considering selling puts among the alternative strategies at their …
Nasdaq8mon
Keryx Biopharmaceuticals, Inc. KERX is expected to report first-quarter 2017 results on May 4. Last quarter, the company missed expectations by 18.52%. In fact, Keryx’s performance over the last four quarters has been disappointing. The …
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters ... have provided all the warning I need to stay away from the stock. But things may be about to change. No, I'm still not interested in …
If you want a Stock Review on CYTR, KERX, TGTX or ZIOP then come over to http://dailystocktracker.com/register and …
Investors in Keryx Biopharmaceuticals, Inc. KERX need to pay close attention to the stock based on moves in the options market lately. That is because the January 19, 2018 $3 Put had some of the highest implied volatility of all equity …
Shares of Keryx Biopharmaceuticals Inc. KERX were down almost 17% on Nov 7 despite receiving FDA approval for a label expansion of its lead drug Auryxia. Lower-than-expected sales of Auryxia in the third quarter led to the selloff. …
A month has gone by since the last earnings report for Keryx Biopharmaceuticals, Inc. KERX. Shares have added about 5% in that time frame, outperforming the market. Will the recent positive trend continue leading up to the stock's next …
Yahoo!10mon